Rigel Pharmaceuticals | RIGL - Ordinary Share Capital


Rigel Pharmaceuticals reported $17K in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agenus USD 38.52M 3.2M Mar/2026
Amgen USD 541M 1000K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 78.5M 11.93M Jun/2026
Daiichi Sankyo JPY 1.82B 30.68M Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.56M 241K Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Veracyte USD 79.79M 1000 Jun/2026